MCID: HYP083
MIFTS: 54

Hypopituitarism malady

Categories: Rare diseases, Endocrine diseases, Genetic diseases

Aliases & Classifications for Hypopituitarism

Aliases & Descriptions for Hypopituitarism:

Name: Hypopituitarism 12 50 29 52 42 14 69
Pituitary Insufficiency 12 50
Pituitary Hormone Deficiency 12
Pituitary Hypofunction 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9406
ICD10 33 E23.0 E23
MeSH 42 D007018
NCIt 47 C62591
UMLS 69 C0020635

Summaries for Hypopituitarism

NIH Rare Diseases : 50 hypopituitarism occurs when the body has low levels of certain hormones made by the pituitary gland.  the pituitary gland normally makes several hormones (including growth hormone, thyroid stimulating hormone, adrenocorticotropic hormone, prolactin, follicle stimulating hormone and luteinizing hormone, vasopressin, and oxytocin).  these hormones are important for directing body growth and development, and for regulating blood pressure and metabolism.  symptoms of this condition vary and depend on which hormones are affected.  treatment depends on the cause of this condition; once the cause is corrected, medication (hormone replacement therapy) must be taken to provide the body with the normal amount of hormones. last updated: 7/20/2012

MalaCards based summary : Hypopituitarism, also known as pituitary insufficiency, is related to chondroma and fatty liver disease. An important gene associated with Hypopituitarism is PROP1 (PROP Paired-Like Homeobox 1), and among its related pathways/superpathways are G-Beta Gamma Signaling and PI3K-Akt signaling pathway. The drugs Testosterone and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and thyroid, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Disease Ontology : 12 A pituitary gland disease characterized by the decreased secretion of one or more of the eight hormones normally produced by the pituitary gland.

Wikipedia : 71 Hypopituitarism is the decreased (hypo) secretion of one or more of the eight hormones normally produced... more...

Related Diseases for Hypopituitarism

Diseases in the Hypopituitarism family:

Familial Hypopituitarism

Diseases related to Hypopituitarism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 319)
id Related Disease Score Top Affiliating Genes
1 chondroma 29.1 IGF1 INS POMC
2 fatty liver disease 28.7 CRH INS POMC PRL
3 pituitary hormone deficiency, combined, 3 12.3
4 pituitary hormone deficiency, combined, 1 12.3
5 choroideremia hypopituitarism 11.9
6 anterior pituitary insufficiency, familial 11.9
7 familial hypopituitarism 11.9
8 sheehan syndrome 11.8
9 corpus callosum dysgenesis hypopituitarism 11.7
10 distal arthrogryposis with hypopituitarism, intellectual disability and facial anomalies 11.7
11 hypopituitarism postaxial polydactyly 11.7
12 isolated growth hormone deficiency 11.3
13 combined pituitary hormone deficiencies, genetic forms 11.2
14 pallister-hall syndrome 11.2
15 lymphocytic hypophysitis 11.1
16 septooptic dysplasia 11.1
17 combined pituitary hormone deficiency 11.1
18 pituitary deficiency due to empty sella turcica syndrome 11.1
19 rhyns syndrome 10.9
20 holoprosencephaly-9 10.8
21 culler-jones syndrome 10.8
22 laurence-moon syndrome 10.8
23 stiff-person syndrome 10.8
24 septo-optic dysplasia spectrum 10.7
25 brain injury 10.3
26 traumatic brain injury 10.3
27 critical congenital heart disease 10.3 GH1 IGF1
28 grin2a-related speech disorders and epilepsy 10.2 GH1 PRL
29 mental retardation, x-linked syndromic, christianson type 10.2 POU1F1 PROP1 SOX3
30 rolandic epilepsy, mental retardation, and speech dyspraxia 10.2 HESX1 SOX3
31 cerebral hemisphere lipoma 10.2 GH1 PRL
32 potter's syndrome 10.2 LHX3 PROP1
33 vaginal adenoma 10.2 IGF1 POMC
34 osseous heteroplasia, progressive 10.2 GH1 IGF1 PRL
35 axial osteomalacia 10.1 GH1 IGF1 PRL
36 dykes markes harper syndrome 10.1 GH1 GHRH IGF1
37 macrocephaly, benign familial 10.1 GH1 POMC
38 blind loop syndrome 10.1 GH1 IGF1 INS
39 sohval soffer syndrome 10.1 IGF1 IGFBP3
40 diabetes insipidus 10.1
41 epidural spinal canal meningioma 10.1 IGF1 INS PRL
42 hyperlipoproteinemia type iii 10.1 INS POMC
43 african histoplasmosis 10.1 POMC PRL
44 aneurysm 10.1
45 pinguecula 10.1 IGF1 INS PRL
46 glaucoma, hereditary adult type 1a 10.1 GH1 GHRH PRL
47 glomangiomyoma 10.1 GH1 INS PRL
48 growth hormone deficiency 10.1
49 spondylometaphyseal dysplasia, megarbane-dagher-melike type 10.0 GH1 IGF1 IGFBP3
50 congenital tricuspid stenosis 10.0 GH1 POMC PRL

Graphical network of the top 20 diseases related to Hypopituitarism:



Diseases related to Hypopituitarism

Symptoms & Phenotypes for Hypopituitarism

MGI Mouse Phenotypes related to Hypopituitarism:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.3 CRH GHRH GLI2 HESX1 IGF1 IGFBP3
2 growth/size/body region MP:0005378 10.21 GLI2 HESX1 IGF1 IGFBP3 INS LHX3
3 homeostasis/metabolism MP:0005376 10.18 CRH GHRH GLI2 IGF1 IGFBP3 INS
4 nervous system MP:0003631 9.97 CRH GHRH GLI2 HESX1 IGF1 INS
5 integument MP:0010771 9.87 CRH GLI2 IGF1 IGFBP3 INS POMC
6 hearing/vestibular/ear MP:0005377 9.8 GLI2 HESX1 IGF1 LHX3 POU1F1
7 liver/biliary system MP:0005370 9.73 IGFBP3 INS POMC PRL CRH GHRH
8 reproductive system MP:0005389 9.61 GHRH GLI2 IGF1 INS LHX3 POU1F1
9 respiratory system MP:0005388 9.1 CRH GLI2 HESX1 IGF1 LHX4 PROP1

Drugs & Therapeutics for Hypopituitarism

Drugs for Hypopituitarism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Testosterone Approved, Investigational Phase 4,Phase 2 58-22-0 6013
2
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2 51-43-4 5816
3
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-23-7 5754 657311
4
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
5
Cosyntropin Approved Phase 4 16960-16-0 16129617
6 insulin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
7 Testosterone undecanoate Phase 4,Phase 2
8 Mitogens Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Cortisol succinate Phase 4,Phase 3,Phase 2,Early Phase 1
10 Testosterone 17 beta-cypionate Phase 4,Phase 2
11
Testosterone enanthate Phase 4,Phase 2 315-37-7 9416
12 Anabolic Agents Phase 4,Phase 2
13 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Androgens Phase 4,Phase 2,Phase 3
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Phase 2,Early Phase 1
18 Hydrocortisone acetate Phase 4,Phase 3,Phase 2,Early Phase 1
19 Epinephryl borate Phase 4,Phase 3,Phase 2
20 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Anti-Inflammatory Agents Phase 4,Early Phase 1
22 Racepinephrine Phase 4,Phase 3,Phase 2
23 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
24 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
25
Zinc Approved Phase 3,Early Phase 1 7440-66-6 32051 23994
26
Clonidine Approved Phase 3 4205-90-7 2803
27
Anastrozole Approved, Investigational Phase 2, Phase 3 120511-73-1 2187
28
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
29
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
30 tannic acid Approved, Nutraceutical Phase 3
31 Anesthetics Phase 2, Phase 3
32 Hypoglycemic Agents Phase 3,Early Phase 1
33 Analgesics Phase 3,Phase 2
34 Adrenergic Agents Phase 3,Phase 2
35 Adrenergic Agonists Phase 3,Phase 2
36 Adrenergic alpha-2 Receptor Agonists Phase 3
37 Adrenergic alpha-Agonists Phase 3,Phase 2
38 Neurotransmitter Agents Phase 3,Phase 2
39 Steroid Synthesis Inhibitors Phase 2, Phase 3
40 Sympatholytics Phase 3
41 Growth Hormone-Releasing Hormone Phase 3,Phase 2,Phase 1
42 Peripheral Nervous System Agents Phase 3,Phase 2
43 Estrogen Antagonists Phase 2, Phase 3
44 Estrogens Phase 2, Phase 3
45 Immunoglobulins Phase 3,Phase 2
46 Antihypertensive Agents Phase 3
47 Respiratory System Agents Phase 2, Phase 3
48 Antibodies Phase 3,Phase 2
49 Aromatase Inhibitors Phase 2, Phase 3
50 Autonomic Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 224)
id Name Status NCT ID Phase
1 Testosterone Gel Applied to Women With Pituitary Gland Problems Unknown status NCT00144391 Phase 4
2 Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test Unknown status NCT00851942 Phase 4
3 Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency Completed NCT00490191 Phase 4
4 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4
5 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia Completed NCT00140413 Phase 4
6 Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation Completed NCT00360074 Phase 4
7 A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood Completed NCT01157793 Phase 4
8 Growth Hormone and Endothelial Function in Children Completed NCT00373386 Phase 4
9 Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD) Completed NCT00097526 Phase 4
10 An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) Completed NCT01806298 Phase 4
11 Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.) Completed NCT01605331 Phase 4
12 Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Completed NCT01562834 Phase 4
13 Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method Completed NCT00990340 Phase 4
14 Growth Hormone and Glucose Metabolism Completed NCT00929799 Phase 4
15 Easypod United States User Trial Completed NCT00689260 Phase 4
16 Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Completed NCT00567385 Phase 4
17 A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency Completed NCT00455884 Phase 4
18 Predictive Markers in GHD and TS Children Treated With SAIZEN® Completed NCT00256126 Phase 4
19 IGF1 Generation Test Completed NCT00145457 Phase 4
20 GH and Cardiovascular Risk Factors Completed NCT01877512 Phase 4
21 First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Completed NCT01419249 Phase 4
22 Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome? Completed NCT01298180 Phase 4
23 Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Completed NCT01245374 Phase 4
24 Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® Completed NCT01187550 Phase 4
25 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4
26 A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood Completed NCT00212758 Phase 4
27 National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients Completed NCT00097513 Phase 4
28 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency Recruiting NCT02976675 Phase 4
29 Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency Recruiting NCT02908958 Phase 4
30 Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children (Clinical Trial I) Recruiting NCT02380235 Phase 4
31 Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj. Recruiting NCT03015909 Phase 4
32 Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children Recruiting NCT02314676 Phase 4
33 A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency Active, not recruiting NCT02311894 Phase 4
34 Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency Terminated NCT01698944 Phase 4
35 A Study to Evaluate the Efficacy of Somatropin in Adults With Growth Hormone Deficiency Caused by Trauma and/or Head Injury Terminated NCT00638053 Phase 4
36 Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury Terminated NCT00555009 Phase 4
37 Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury. Withdrawn NCT00432263 Phase 4
38 Treatment of Children With Insufficient Secretion of Growth Hormone Unknown status NCT00271518 Phase 3
39 Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys Completed NCT00133354 Phase 2, Phase 3
40 Treatment of Adrenal Insufficiency in Children Completed NCT02720952 Phase 3
41 Genotropin Study Assessing Use of Injection Pen Completed NCT00965484 Phase 3
42 Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary Completed NCT00174278 Phase 3
43 Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency Completed NCT00109733 Phase 3
44 Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency Completed NCT02693522 Phase 3
45 Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency Completed NCT02558829 Phase 3
46 A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency Completed NCT02382939 Phase 3
47 A Follow-up Study to Examine the Presence of Anti-human Growth Hormone Antibodies Following a Study (FE 999905 CS07) of Zomacton in Children With Growth Hormone Deficiency Completed NCT02173821 Phase 3
48 Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency Completed NCT01502124 Phase 3
49 Phase III Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children Completed NCT01495468 Phase 3
50 Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects Completed NCT01112865 Phase 3

Search NIH Clinical Center for Hypopituitarism

Cochrane evidence based reviews: hypopituitarism

Genetic Tests for Hypopituitarism

Genetic tests related to Hypopituitarism:

id Genetic test Affiliating Genes
1 Hypopituitarism 29

Anatomical Context for Hypopituitarism

MalaCards organs/tissues related to Hypopituitarism:

39
Pituitary, Brain, Thyroid, Testes, Bone, Endothelial, B Cells

Publications for Hypopituitarism

Articles related to Hypopituitarism:

(show top 50) (show all 705)
id Title Authors Year
1
CARDIAC STRUCTURAL AND FUNCTIONAL ABNORMALITIES IN FEMALES WITH UNTREATED HYPOPITUITARISM DUE TO SHEEHAN SYNDROME: RESPONSE TO HORMONE REPLACEMENT THERAPY. ( 27359291 )
2016
2
Unusual association of turner syndrome and hypopituitarism in a Tunisian family. ( 27140594 )
2016
3
The effect of growth hormone replacement on the thyroid axis in patients with hypopituitarism: in vivo and ex vivo studies. ( 27809356 )
2016
4
Loperamide-induced hypopituitarism. ( 27681351 )
2016
5
The effect of hypopituitarism on fatigue after subarachnoid hemorrhage. ( 27128968 )
2016
6
Bilateral Carotid-Cavernous Fistulas: An Uncommon Cause of Pituitary Enlargement and Hypopituitarism. ( 27651959 )
2016
7
The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke. ( 27815769 )
2016
8
HESX1 Mutations in Patients with Congenital Hypopituitarism: Variable Phenotypes with the Same Genotype. ( 27000987 )
2016
9
Hypopituitarism patterns among adult males with prolactinomas. ( 27038873 )
2016
10
Circulating MicroRNAs as Potential Biomarkers for Traumatic Brain Injury-Induced Hypopituitarism. ( 27027233 )
2016
11
Recovery of adrenal function after chronic secondary adrenal insufficiency in patients with hypopituitarism. ( 26928716 )
2016
12
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. ( 27736313 )
2016
13
Neuroendocrine Disturbances One to Five or More Years after Traumatic Brain Injury and Aneurysmal Subarachnoid Hemorrhage: Data from the German Database on Hypopituitarism. ( 26914840 )
2016
14
Hypopituitarism: An uncommon cause of developmental delay. ( 27452620 )
2016
15
A patient with pseudohypoaldosteronism type II complicated by congenital hypopituitarism carrying a KLHL3 mutation. ( 27780982 )
2016
16
Cancerous leptomeningitis and familial congenital hypopituitarism. ( 26886902 )
2016
17
A unique case of Shwachman-Diamond syndrome presenting with congenital hypopituitarism. ( 27754968 )
2016
18
Reversible Hypopituitarism Associated with Intravascular Large B-Cell Lymphoma: Case Report of Successful Immunochemotherapy. ( 26936510 )
2016
19
Cholesteatoma in the Sellar Region Presenting as Hypopituitarism and Diabetes Insipidus. ( 26962793 )
2016
20
Endocrinology Update: Hypopituitarism. ( 27936532 )
2016
21
Hypopituitarism in the elderly: a narrative review on clinical management of hypothalamic-pituitary-gonadal, hypothalamic-pituitary-thyroid and hypothalamic-pituitary-adrenal axes dysfunction. ( 27209187 )
2016
22
Growth hormone deficiency and hypopituitarism in adults after complicated mild traumatic brain injury. ( 27878771 )
2016
23
Evaluation and Initial Management of Hypopituitarism. ( 27587639 )
2016
24
Partial hypopituitarism in a female patient with a 45,X/46,XY mosaicism. ( 27988022 )
2016
25
IGF-I levels reflect hypopituitarism severity in adults with pituitary dysfunction. ( 27083162 )
2016
26
Hypopituitarism Presenting as Adrenal Insufficiency and Hypothyroidism in a Patient with Wilson's Disease: a Case Report. ( 27478349 )
2016
27
HORMONE SUBSTITUTION AFTER GASTRIC BYPASS SURGERY IN PATIENTS WITH HYPOPITUITARISM SECONDARY TO CRANIOPHARYNGIOMA. ( 26789341 )
2016
28
Four-year follow-up of a Wilson disease pedigree complicated with epilepsy and hypopituitarism: Case report with a literature review. ( 27930511 )
2016
29
VARIATIONS IN CLINICAL AND IMAGING FINDINGS BY TIME OF DIAGNOSIS IN FEMALES WITH HYPOPITUITARISM ATTRIBUTED TO LYMPHOCYTIC HYPOPHYSITIS. ( 26595515 )
2016
30
Anterior Hypopituitarism and Treatment Response in Hunter Syndrome: A Comparison of Two Patients. ( 28018694 )
2016
31
Regulation of fuel metabolism during exercise in hypopituitarism with growth hormone-deficiency (GHD). ( 27084998 )
2016
32
Hypopituitarism following rifle cleaning accident. ( 27934815 )
2016
33
A case of hypopituitarism accompanying Kearns-Sayre syndrome treated with human chorionic gonadotropin: A case report and literature review. ( 27709644 )
2016
34
Intraparenchymal infiltration of Rathke's cleft cysts manifesting as severe neurological deficits and hypopituitarism: 2 case reports. ( 27094461 )
2016
35
Concurrent hypopituitarism and leukemic retinopathy in a child with B-precursor acute lymphoblastic leukemia and isolated central nervous system relapse. ( 27536191 )
2016
36
Hypopituitarism in children with cerebral palsy. ( 27789461 )
2016
37
Hypopituitarism. ( 27041067 )
2016
38
Mortality in adults with hypopituitarism: a systematic review and meta-analysis. ( 27817141 )
2016
39
Hypopituitarism and goitre as endocrine manifestation of Langerhans cell histiocytosis (LCH). Case Report. ( 27618599 )
2016
40
How should we interrogate the hypothalamic-pituitary-adrenal axis in patients with suspected hypopituitarism? ( 27316460 )
2016
41
Hypopituitarism-needs modern individualized treatment. ( 28004235 )
2016
42
Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies. ( 25658016 )
2015
43
A Rare Case of Isolated Cerebral Sarcoidosis Presenting as Suprasellar Mass Lesion with Salt-Wasting Hypopituitarism. ( 26251792 )
2015
44
Patient reported outcome in posttraumatic pituitary deficiency: results from The Danish National Study on posttraumatic hypopituitarism. ( 25766045 )
2015
45
Comments on Auble et al. Regarding Hypopituitarism in Pediatric Survivors of Inflicted Traumatic Brain Injury. ( 26414281 )
2015
46
Characterization of facial phenotypes of children with congenital hypopituitarism and their parents: A matched case-control study. ( 25845580 )
2015
47
Clinical and diagnostic approach to patients with hypopituitarism due to traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), and ischemic stroke (IS). ( 26573924 )
2015
48
Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study. ( 25559807 )
2015
49
Decreased apparent diffusion coefficient in the pituitary and correlation with hypopituitarism in patients with traumatic brain injury. ( 25679273 )
2015
50
A Case of IgG4-Related Hypophysitis Presented with Hypopituitarism and Diabetes Insipidus. ( 25861230 )
2015

Variations for Hypopituitarism

Expression for Hypopituitarism

Search GEO for disease gene expression data for Hypopituitarism.

Pathways for Hypopituitarism

GO Terms for Hypopituitarism

Cellular components related to Hypopituitarism according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.92 CRH GH1 GHRH IGF1 IGFBP3 INS
2 extracellular space GO:0005615 9.8 CRH GH1 GHRH IGF1 IGFBP3 INS
3 insulin-like growth factor ternary complex GO:0042567 9.16 IGF1 IGFBP3
4 insulin-like growth factor binding protein complex GO:0016942 8.96 IGF1 IGFBP3
5 endosome lumen GO:0031904 8.8 GH1 INS PRL

Biological processes related to Hypopituitarism according to GeneCards Suite gene sharing:

(show all 30)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.92 GLI2 IGF1 LHX3 LHX4 PROP1
2 cellular protein metabolic process GO:0044267 9.8 IGF1 IGFBP3 INS PRL
3 animal organ morphogenesis GO:0009887 9.79 LHX3 LHX4 PROP1
4 lung development GO:0030324 9.75 CRH GLI2 LHX3
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.73 GH1 IGF1 INS
6 positive regulation of MAPK cascade GO:0043410 9.71 IGF1 IGFBP3 INS
7 positive regulation of cell proliferation GO:0008284 9.7 CRH GHRH GLI2 IGF1 INS POU1F1
8 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.69 GH1 IGF1 INS
9 activation of protein kinase B activity GO:0032148 9.65 IGF1 INS
10 positive regulation of mitotic nuclear division GO:0045840 9.64 IGF1 INS
11 motor neuron axon guidance GO:0008045 9.64 LHX3 LHX4
12 positive regulation of JAK-STAT cascade GO:0046427 9.63 GH1 PRL
13 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.61 GH1 IGF1
14 positive regulation of glycogen biosynthetic process GO:0045725 9.61 IGF1 INS
15 dorsal/ventral pattern formation GO:0009953 9.61 GLI2 LHX3 PROP1
16 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.6 GH1 PRL
17 hypothalamus development GO:0021854 9.59 CRH SOX3
18 positive regulation of glycolytic process GO:0045821 9.58 IGF1 INS
19 positive regulation of DNA replication GO:0045740 9.58 GLI2 IGF1 INS
20 parturition GO:0007567 9.55 CRH PRL
21 positive regulation of multicellular organism growth GO:0040018 9.54 GH1 GHRH POU1F1
22 regulation of insulin-like growth factor receptor signaling pathway GO:0043567 9.48 IGFBP3 POU1F1
23 somatotropin secreting cell differentiation GO:0060126 9.46 POU1F1 PROP1
24 adenohypophysis development GO:0021984 9.43 GHRH POU1F1 PROP1
25 medial motor column neuron differentiation GO:0021526 9.32 LHX3 LHX4
26 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.26 GH1 GHRH IGF1 IGFBP3
27 pituitary gland development GO:0021983 9.02 GLI2 HESX1 LHX3 POU1F1 SOX3
28 regulation of transcription, DNA-templated GO:0006355 10.23 GLI2 HESX1 INS LHX3 LHX4 POU1F1
29 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.04 GLI2 IGF1 LHX3 POMC POU1F1 PROP1
30 negative regulation of transcription from RNA polymerase II promoter GO:0000122 10.02 GLI2 HESX1 POU1F1 PROP1 SOX3

Molecular functions related to Hypopituitarism according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.67 GLI2 HESX1 POU1F1 PROP1
2 sequence-specific DNA binding GO:0043565 9.63 GLI2 HESX1 LHX3 LHX4 POU1F1 PROP1
3 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000978 9.62 GLI2 HESX1 LHX3 POU1F1
4 insulin-like growth factor receptor binding GO:0005159 9.26 IGF1 INS
5 hormone activity GO:0005179 9.1 CRH GH1 IGF1 INS POMC PRL
6 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Hypopituitarism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....